ISIN | LU1587985067 |
---|---|
No. de valeur | |
Bloomberg Global ID | |
Nom de fond | Bellevue Asia Pacific Healthcare I2 CHF |
Prestataire de fonds |
Bellevue Asset Management AG
Zürich, Suisse Téléphone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Prestataire de fonds | Bellevue Asset Management AG |
Représentant en Suisse |
Waystone Fund Services (Switzerland) SA Lausanne Téléphone: 0041213111781 |
Distributeur(s) |
Bank am Bellevue AG Küsnacht Téléphone: +41 44 267 67 67 |
Classe d'actifs | Fonds en actions |
EFC Catégorie | |
Catégorie de parts | Accumulation |
Pays d'origine | Luxembourg |
Conditions d'émission de parts | Combinaison de commission d'émission en faveur de la direction du fonds et frais de transaction en faveur du fonds |
Conditions de rachat de parts | Combinaison de commission de rachat en faveur de la direction du fonds et frais de transaction en faveur du fonds |
Stratégie d'investissement *** | The sub-fund is an equity fund. The investment objective of the sub-fund is to achieve long-term capital growth by investing at least two thirds of the net assets of the fund in a portfolio of carefully chosen shares and other equity securities of companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of the Asia-Pacific region. The universe for companies is determined cumulatively as follows: Shares of companies that have their registered office or carry out the majority of their economic activity in the healthcare sector in the Asia-Pacific region. These include companies operating in such areas as generics, medtech, biotech, pharma and health services which are involved in the development, manufacture or sale of products and services. Listed on a recognised stock market or, in the case of an initial public offering, the company has applied for listing on the relevant exchange. |
Particularités |
Prix actuel * | 141.85 CHF | 14.11.2024 |
---|---|---|
Prix précédent * | 142.10 CHF | 13.11.2024 |
Max 52 semaines * | 155.47 CHF | 04.10.2024 |
Min 52 semaines * | 135.03 CHF | 05.08.2024 |
NAV * | 141.85 CHF | 14.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Prix minimal indicatif | ||
Actifs du fonds *** | 115'516'409 | |
Actifs de la classe *** | ||
Trading Information SIX |
YTD Performance | -0.58% |
29.12.2023 - 14.11.2024
29.12.2023 14.11.2024 |
---|---|---|
1 mois | -7.66% |
15.10.2024 - 14.11.2024
15.10.2024 14.11.2024 |
3 mois | -3.39% |
14.08.2024 - 14.11.2024
14.08.2024 14.11.2024 |
6 mois | -2.12% |
14.05.2024 - 14.11.2024
14.05.2024 14.11.2024 |
1 an | -3.89% |
14.11.2023 - 14.11.2024
14.11.2023 14.11.2024 |
2 ans | -16.10% |
14.11.2022 - 14.11.2024
14.11.2022 14.11.2024 |
3 ans | -40.73% |
15.11.2021 - 14.11.2024
15.11.2021 14.11.2024 |
5 ans | -46.80% |
15.06.2021 - 14.11.2024
15.06.2021 14.11.2024 |
Quota de participation de capital en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Part de la fortune du fonds en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quota d'immobilier en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Daiichi Sankyo Co Ltd | 8.41% | |
---|---|---|
Hoya Corp | 6.40% | |
CSL Ltd | 5.90% | |
Otsuka Holdings Co Ltd | 5.01% | |
Olympus Corp | 4.88% | |
Akeso Inc Ordinary Shares | 4.75% | |
Legend Biotech Corp ADR | 4.64% | |
Samsung BioLogics Co Ltd | 4.56% | |
BeiGene Ltd ADR | 4.45% | |
Innovent Biologics Inc | 4.11% | |
Dernière mise à jour des données | 31.10.2024 |
TER | 1.52% |
---|---|
Date TER | 29.01.2021 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.48% |
SRRI ***
|
|
Date SRRI *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |